These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 10391672

  • 21. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 22. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M, Bodtländer A, Knecht GK, Stephan C, von Hentig N, Kurowski M, Gute P, Klauke S, Lutz T.
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [Abstract] [Full Text] [Related]

  • 23. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
    Florence E, Dreezen C, Desmet P, Smets E, Fransen K, Vandercam B, Pelgrom J, Clumeck N, Colebunder R.
    Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, Lumbiganon P, Burger D, Ruxrungtham K, Schutz M, Ananworanich J, HIV-NAT 017 Study Team.
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
    Vazquez E.
    Posit Aware; 1996 Jul; 7(6):8-9. PubMed ID: 11363983
    [Abstract] [Full Text] [Related]

  • 30. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
    Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K, Staccato Study Team.
    Antivir Ther; 2006 Jul; 11(5):631-5. PubMed ID: 16964832
    [Abstract] [Full Text] [Related]

  • 31. A pilot study of a combination of three reverse transcriptase inhibitors in HIV-1 infection.
    Lafeuillade A, Poggi C, Djediouane A, Chollet L, Profizi N, Sayada C.
    Antivir Ther; 1997 Dec; 2(4):219-27. PubMed ID: 11327441
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.
    Lorenzi P, Yerly S, Abderrakim K, Fathi M, Rutschmann OT, von Overbeck J, Leduc D, Perrin L, Hirschel B.
    AIDS; 1997 Oct; 11(12):F95-9. PubMed ID: 9342060
    [Abstract] [Full Text] [Related]

  • 34. Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals.
    Soria A, Gianotti N, Cernuschi M, Lazzarin A.
    New Microbiol; 2004 Jan; 27(1):11-5. PubMed ID: 14964400
    [Abstract] [Full Text] [Related]

  • 35. [Clinical and immuno-virologic efficacy of the expanded access use of protease inhibitors for HIV-1 advanced disease].
    Gómez-Vera J, De Alarcón A, Viciana P, Del Nozal Nalda M, Cordero E, Rodríguez-Hernández MJ, Pachón J.
    An Med Interna; 1999 May; 16(5):218-24. PubMed ID: 10389305
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086
    [Abstract] [Full Text] [Related]

  • 38. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
    Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M.
    Antimicrob Agents Chemother; 2007 Jun 10; 51(6):2035-42. PubMed ID: 17371813
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD.
    AIDS; 1999 Jul 30; 13(11):F71-7. PubMed ID: 10449277
    [Abstract] [Full Text] [Related]

  • 40. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S, GESIDA 7011 Study Group.
    Lancet Infect Dis; 2015 Jul 30; 15(7):775-84. PubMed ID: 26062881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.